SCHEMBL148122

SCHEMBL148122

N[C@H](Cc1ccc(C(F)(F)F)cc1)C(=O)O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRB2 P62993 1/20 0.76
PTPN1 P18031 2/20 0.69
SLC7A5 Q01650 3/20 0.62
PTGS1 P23219 3/20 0.61
ALPI P09923 1/20 0.61
PKM P14618 1/20 0.61
XIAP P98170 1/20 0.61
TPH1 P17752 3/20 0.58
KIF11 P52732 1/20 0.55
ALOX15 P16050 3/20 0.53
HIF1A Q16665 3/20 0.53
KDM4E B2RXH2 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
USP2 O75604 1/20 0.53
EGFR P00533 1/20 0.53
LCK P06239 1/20 0.53
FYN P06241 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
HTR2A P28223 1/20 0.53
PTGS2 P35354 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL43862 1.00 GRB2 (0.76) GRB2PTPN1SLC7A5PTGS1ALPI
SCHEMBL43861 1.00 GRB2 (0.76) GRB2PTPN1SLC7A5PTGS1ALPI
Hydrochloric Acid SCHEMBL4364332 0.98 GRB2 (0.73) GRB2PTPN1SLC7A5PTGS1ALPI
Hydrochloric Acid SCHEMBL16289248 0.98 GRB2 (0.73) GRB2PTPN1SLC7A5PTGS1ALPI
Hydrochloric Acid SCHEMBL29399075 0.98 GRB2 (0.73) GRB2PTPN1SLC7A5PTGS1ALPI
Dl-Phenylalanine SCHEMBL28313877 0.95 SLC7A5 (0.71) GRB2PTPN1SLC7A5PTGS1ALPI
SCHEMBL28901130 0.94 GRB2 (0.68) GRB2PTPN1SLC7A5PTGS1ALPI
SCHEMBL28901132 0.94 GRB2 (0.68) GRB2PTPN1SLC7A5PTGS1ALPI
SCHEMBL13205275 0.92 GRB2 (0.66) GRB2PTPN1SLC7A5PTGS1ALPI
SCHEMBL21803821 0.91 GRB2 (0.64) GRB2PTPN1SLC7A5PTGS1ALPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 519 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025151135-A1 METHODS OF TREATING CANCER AND/OR CHEMOTHERAPY RELATED CONDITIONS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS ENDEVICA BIO, INC. (US) 2025-07-17 WO claimed
WO-2025123055-A1 NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS AND ASSOCIATED METHODS FOR MODULATING WEIGHT GAIN ENDEVICA BIO, INC. (US) 2025-06-12 WO claimed
EP-4444740-A2 P53 PEPTIDOMIMETIC MACROCYCLES Merck Sharp & Dohme LLC (US) 2024-10-16 EP claimed
CN-116730969-A Beta-lapachone-amino acid conjugate, and preparation method and application thereof 中国药科大学 2023-09-12 CN claimed
WO-2023107353-A2 P53 PEPTIDOMIMETIC MACROCYCLES MERCK SHARP & DOHME LLC (US) 2023-06-15 WO claimed
EP-4100064-A1 TARGETED PLASMA PROTEIN DEGRADATION Novartis AG (CH) 2022-12-14 EP claimed
CN-115335081-A Targeted plasma protein degradation 诺华股份有限公司 2022-11-11 CN claimed
US-11274126-B2 pH-sensitive cyclic peptides UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) 2022-03-15 US claimed
WO-2021156792-A1 TARGETED PLASMA PROTEIN DEGRADATION NOVARTIS AG (CH) 2021-08-12 WO claimed
EP-3432908-A1 pH-SENSITIVE PEPTIDES Rhode Island Council on Postsecondary Education (US) 2019-01-30 EP claimed
WO-2017165452-A1 pH-SENSITIVE PEPTIDES RHODE ISLAND COUNCIL ON POSTSECONDARY EDUCATION (US) 2017-09-28 WO claimed
CN-106986495-A A kind of removable movable pot integrated sewage treating apparatus and its method of work 徐州工程学院 2017-07-28 CN claimed
WO-2009100441-A2 DEPOT FORMULATIONS IMPAX LABORATORIES, INC. (US) 2009-08-13 WO claimed
US-20260083834-A1 CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY TRANSFERT PLUS LP (CA) 2026-03-26 US disclosed
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME NEW YORK UNIVERSITY (US) 2026-01-01 US disclosed
US-20250367300-A1 Nanomaterial and Methods of Use Thereof UNIVERSITY OF CONNECTICUT (US) 2025-12-04 US disclosed
EP-1109831-A2 CYCTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES ALPHARMA AS (NO) 2001-06-27 EP disclosed
EP-1109827-A2 BIOACTIVE PEPTIDES ALPHARMA AS (NO) 2001-06-27 EP disclosed
WO-2000012542-A2 CYTOTOXIC LACTOFERRIN DERIVATIVES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES ALPHARMA AS (NO) 2000-03-09 WO disclosed
WO-2000012541-A2 CYTOTOXIC PEPTIDES MODIFIED BY BULKY OR LIPOPHILIC MOIETIES ALPHARMA AS (NO) 2000-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11274126-B2 pH-sensitive cyclic peptides VIP, PHLPP1, PHLPP2 GRB2 1995/4885PTPN1 1659/4885SLC7A5 227/4885
US-20250367300-A1 Nanomaterial and Methods of Use Thereof EPCAM, CD47, JAK2 GRB2 2365/4885PTPN1 26/4885SLC7A5 1405/4885
US-20260083834-A1 CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY VSIG8, MICA, CD74 GRB2 2704/4885PTPN1 1570/4885SLC7A5 1741/4885
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME DDX21, PHAX, RBX1 GRB2 2544/4885PTPN1 2490/4885SLC7A5 3352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.